Doctors warn biotin supplements may disrupt cancer lab testing

A common supplement is getting fresh scrutiny in oncology

Biotin supplements are widely marketed for stronger hair and nails, and that message has found a receptive audience among cancer patients coping with treatment-related hair loss. But clinicians at Ohio State University are warning that the vitamin can create a more serious problem: inaccurate lab results that may interfere with care.

The concern, described in material released through ScienceDaily, comes from Brittany Dulmage, an oncodermatologist at The Ohio State University Comprehensive Cancer Center and associate director of dermatology at the College of Medicine. Dulmage argues that the perceived harmlessness of biotin has obscured a meaningful clinical risk. In her view, the supplement can distort blood markers in ways that affect how doctors assess recurrence or make treatment decisions.

That makes this a medical communication problem as much as a supplement problem. Many patients start taking biotin on their own after seeing recommendations online, hearing about it from friends, or sometimes even receiving informal advice in clinical settings. The result is that a routine attempt to address hair loss can spill into the diagnostic side of cancer care.

Why patients take it and why doctors are worried

Hair loss remains one of the most distressing side effects associated with cancer treatment. It is therefore unsurprising that patients look for accessible options that appear low-risk. Biotin, also known as vitamin B7, is commonly associated with keratin production, which is linked to hair, skin and nails. That marketing narrative has helped turn it into a familiar over-the-counter choice.

The problem is that the evidence supporting oral biotin for cancer-related hair or nail regrowth is weak, according to the source material. At the same time, the potential downside is not theoretical. Dulmage says the supplement may produce inaccurate lab results, with the possibility of delaying or changing treatment plans.

In cancer care, even modest distortions in test interpretation can matter. A biomarker that appears normal when it should not be, or abnormal when it is not, can shape follow-up timing, further testing and clinical confidence. The warning here is not that biotin causes cancer progression. It is that it may cloud the information doctors rely on to monitor patients.

The larger issue is disclosure

One reason this risk persists is that supplements often sit outside the way patients think about medications. People may mention prescriptions during appointments but omit vitamins, hair products or over-the-counter regimens because they assume those items are minor. Dulmage’s comments suggest that biotin falls squarely into that blind spot.

That matters because true biotin deficiency is uncommon. The vitamin is already found in foods including fruits, vegetables, meat, eggs and dairy products, according to the source text. If deficiency is rare and evidence of benefit for treatment-related hair loss is limited, the threshold for accepting testing interference should be very low.

Dulmage authored a paper in JCO Oncology Practice to push for more direct conversations between oncologists and patients about hair loss and supplement use. That recommendation points to a practical fix: normalize the discussion early rather than waiting for a lab anomaly or a confusing result.

Key takeaways from the warning

Biotin is commonly used by patients trying to address cancer-related hair loss.
The source material says there is little scientific evidence that oral biotin helps with that problem in this setting.
Doctors are concerned the supplement can interfere with lab testing and distort blood markers.
The risk is serious because inaccurate results can affect treatment timing and decision-making.

Doctors caution cancer patients on biotin after concerns over distorted lab results

A common supplement is getting fresh scrutiny in oncology

Why patients take it and why doctors are worried

Keep Reading

أعاد كائن طلائعي من بركة كتابة إحدى قواعد علم الأحياء «العالمية»

The larger issue is disclosure

Key takeaways from the warning

Why this matters beyond one vitamin

يحمل المذنب بين النجمي 3I/ATLAS ماءً ثقيلاً لا يشبه أي شيء شوهد في النظام الشمسي

A narrow but important message

Comments (0)